Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Other Events
9 Apr 24
8-K
Departure of Directors or Certain Officers
20 Mar 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
4 Oct 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
8-K
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
7 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates
8 May 23
8-K/A
Departure of Directors or Certain Officers
5 May 23
8-K
Viracta Therapeutics Announces Departure of Chief Medical Officer
2 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
8-K
Departure of Directors or Certain Officers
31 Mar 23
S-8
Registration of securities for employees
14 Mar 23
10-K
2022 FY
Annual report
14 Mar 23
8-K
Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
13 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs
10 Nov 22
8-K
Viracta Therapeutics’ Board of Directors appoints Mark Rothera as President and Chief Executive Officer
19 Sep 22
8-K
First Amendment to Loan and Security Agreement
26 Aug 22
8-K
Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors
11 Aug 22
8-K
Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
9 Aug 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
S-8
Registration of securities for employees
27 Jun 22
8-K
Departure of Directors or Certain Officers
8 Jun 22
10-Q
2022 Q1
Quarterly report
10 May 22
8-K
Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
10 May 22
8-K
Departure of Directors or Certain Officers
27 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 22
Latest ownership filings
3
Melody Burcar
22 Mar 24
4
Mark Rothera
13 Mar 24
4
Darrel P. Cohen
13 Mar 24
4
Daniel R. Chevallard
13 Mar 24
144
Notice of proposed sale of securities
27 Feb 24
4
IVOR ROYSTON
27 Feb 24
4
Roger Pomerantz
27 Feb 24
4
Daniel R. Chevallard
27 Feb 24
SC 13G
FORWARD VENTURES V LP
13 Feb 24
4
Mark Rothera
4 Dec 23
4
Daniel R. Chevallard
28 Nov 23
4
IVOR ROYSTON
28 Nov 23
4
Roger Pomerantz
28 Nov 23
4
IVOR ROYSTON
29 Aug 23
4
Roger Pomerantz
29 Aug 23
4
Daniel R. Chevallard
29 Aug 23
4
Roger Pomerantz
18 Aug 23
4
Darrel P. Cohen
18 Aug 23
3
Darrel P. Cohen
16 Aug 23
4
Barry J. Simon
9 Jun 23
4
Stephen Rubino
9 Jun 23
4
IVOR ROYSTON
9 Jun 23
4
Roger Pomerantz
9 Jun 23
4
Samuel Lafayette Murphy
9 Jun 23
4
THOMAS E DARCY
9 Jun 23
4
Jane Chung
9 Jun 23
4
Flavia Borellini
9 Jun 23
4
Jane F Barlow
9 Jun 23
4
IVOR ROYSTON
26 May 23
4
Roger Pomerantz
26 May 23
4
Daniel R. Chevallard
26 May 23
144
Notice of proposed sale of securities
26 May 23
4
Mark Rothera
17 Mar 23
4
Lisa Rojkjaer
17 Mar 23
4
Daniel R. Chevallard
17 Mar 23
4
IVOR ROYSTON
28 Feb 23
4
Lisa Rojkjaer
28 Feb 23
4
Roger Pomerantz
28 Feb 23
4
Daniel R. Chevallard
28 Feb 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23